Is AbbVie Inc. (NYSE:ABBV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating AbbVie Inc. at current levels.
Humira's death was supposed to break AbbVie. Skyrizi and Rinvoq buried that narrative, and the next leg starts now.
Where ABBV is headed
The Humira cliff was meant to be the end of the story. Instead, by mid-2027, Skyrizi and Rinvoq will be running at a combined $35 billion-plus annual revenue pace, comfortably eclipsing Humira's peak and doing it across a broader basket of indications (psoriasis, Crohn's, UC, RA, atopic dermatitis, and the pipeline filings still landing). That is not a recovery story. That is a portfolio that did the hardest thing in biopharma, replaced its anchor before the anchor sank the ship.
Read the full Compass Direction on ABBV
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $225.42).
See the full ABBV analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is AbbVie Inc. (NYSE:ABBV) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating AbbVie Inc. at current levels. Humira's death was supposed to break AbbVie. Skyrizi and Rinvoq buried that narrative, and the next leg starts now.
What is ABBV's Compass Score?
AbbVie Inc. scores 34/100 on Alexandria's Compass, placing it in the "Headwinds" tier. Scores blend eight factors and update weekly.
What is the price target for ABBV?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the ABBV page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.